Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study | Zendy

Melanie Chin | Zendy; George L. Bakris | Zendy; Geoffrey A. Block | Zendy; Glenn M. Chertow | Zendy; Angie Goldsberry | Zendy; Lesley A. Inker | Zendy; Hiddo J.L. Heerspink | Zendy; Megan O’Grady | Zendy; Pablo E. Pérgola | Zendy; Christoph Wanner | Zendy; David G. Warnock | Zendy; Colin J. Meyer | Zendy

Open Access

Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study

Author(s) -

Melanie Chin,

George L. Bakris,

Geoffrey A. Block,

Glenn M. Chertow,

Angie Goldsberry,

Lesley A. Inker,

Hiddo J.L. Heerspink,

Megan O’Grady,

Pablo E. Pérgola,

Christoph Wanner,

David G. Warnock,

Colin J. Meyer

Publication year - 2018

Publication title -

american journal of nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.394

H-Index - 85

eISSN - 1421-9670

pISSN - 0250-8095

DOI - 10.1159/000486398

Subject(s) - medicine , renal function , kidney disease , type 2 diabetes , placebo , urology , post hoc analysis , kidney , clinical endpoint , gastroenterology , endocrinology , creatinine , diabetes mellitus , randomized controlled trial , pathology , alternative medicine

Increases in measured inulin clearance, measured creatinine clearance, and estimated glomerular filtration rate (eGFR) have been observed with bardoxolone methyl in 7 studies enrolling approximately 2,600 patients with type 2 diabetes (T2D) and chronic kidney disease (CKD). The largest of these studies was Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes (BEACON), a multinational, randomized, double-blind, placebo-controlled phase 3 trial which enrolled patients with T2D and CKD stage 4. The BEACON trial was terminated after preliminary analyses showed that patients randomized to bardoxolone methyl experienced significantly higher rates of heart failure events. We performed post-hoc analyses to characterize changes in kidney function induced by bardoxolone methyl.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research